BRPI0915326A2 - Inibidores fxa como amidoxima ciclina ou amidrozona ciclica como sub unidade p4, processos para suas preparações e preparações farmacêuticas e derivados dos mesmos - Google Patents

Inibidores fxa como amidoxima ciclina ou amidrozona ciclica como sub unidade p4, processos para suas preparações e preparações farmacêuticas e derivados dos mesmos

Info

Publication number: BRPI0915326A2
Authority: BR; Brazil
Prior art keywords: preparations; cycloamidoxime; subunit; inhibitors; derivatives
Prior art date: 2008-07-03

Application number

BRPI0915326-8A

Other languages

English (en)

Inventor

Ho Young Song

Young Lag Cho

Dae Yon Lee

Hee Sock Park

Sung Yoon Baek

Sang Eun Chae

Sang Hui Jo

Yeon Ok Kim

Hyang Sook Lee

Ju Hyun Park

Tae Kyo Park

Sung Ho Woo

Yong Zu Kim

Original Assignee

Legochem Bioscience Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-03

Filing date

2009-06-05

Publication date

2015-08-04

2009-06-05 Application filed by Legochem Bioscience Ltd filed Critical Legochem Bioscience Ltd

2015-08-04 Publication of BRPI0915326A2 publication Critical patent/BRPI0915326A2/pt

2021-04-06 Publication of BRPI0915326B1 publication Critical patent/BRPI0915326B1/pt

2021-05-25 Publication of BRPI0915326B8 publication Critical patent/BRPI0915326B8/pt

Links

SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 title 1
125000004122 cyclic group Chemical group 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0915326A 2008-07-03 2009-06-05 derivado de oxazolidinona com grupo amidrazona cíclica ou amidoxima cíclica e composição farmacêutica BRPI0915326B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR1020080064178A KR100898361B1 (ko)	2008-07-03	2008-07-03	Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
KR10-2008-0064178		2008-07-03
PCT/KR2009/003008 WO2010002115A2 (en)	2008-07-03	2009-06-05	Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof

Publications (3)

Publication Number	Publication Date
BRPI0915326A2 true BRPI0915326A2 (pt)	2015-08-04
BRPI0915326B1 BRPI0915326B1 (pt)	2021-04-06
BRPI0915326B8 BRPI0915326B8 (pt)	2021-05-25

Family

ID=40862256

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0915326A BRPI0915326B8 (pt)	2008-07-03	2009-06-05	derivado de oxazolidinona com grupo amidrazona cíclica ou amidoxima cíclica e composição farmacêutica

Country Status (17)

Country	Link
US (1)	US8178525B2 (pt)
EP (1)	EP2307407B1 (pt)
JP (1)	JP5325289B2 (pt)
KR (1)	KR100898361B1 (pt)
CN (1)	CN102083825B (pt)
AU (1)	AU2009266631B2 (pt)
BR (1)	BRPI0915326B8 (pt)
CA (1)	CA2728350C (pt)
CL (1)	CL2010001618A1 (pt)
ES (1)	ES2566755T3 (pt)
IL (1)	IL210384A (pt)
MX (1)	MX2010013969A (pt)
MY (1)	MY165573A (pt)
NZ (1)	NZ590315A (pt)
RU (1)	RU2468024C2 (pt)
UA (1)	UA97598C2 (pt)
WO (1)	WO2010002115A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101023174B1 (ko) *	2008-09-24	2011-03-18	주식회사 레고켐 바이오사이언스	사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
KR101037051B1 (ko)	2009-07-08	2011-05-26	주식회사 레고켐 바이오사이언스	(ｓ)-5-클로로-ｎ-((3-(4-(5,6-다이하이드로-4ｈ-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법
KR101037052B1 (ko) *	2009-07-08	2011-05-26	주식회사 레고켐 바이오사이언스	5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체
GEP20156397B (en) *	2011-05-06	2015-11-10	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Process for the preparation of a rivaroxaban and intermediates formed in said process
US8877628B2 (en)	2012-07-12	2014-11-04	Micron Technologies, Inc.	Methods of forming nano-scale pores, nano-scale electrical contacts, and memory devices including nano-scale electrical contacts, and related structures and devices
CN110407827B (zh) *	2014-07-18	2023-05-23	株式会社绿十字	Gcc-4401c的晶形和包含所述晶形的药物组合物
CN114591337A (zh) *	2022-03-31	2022-06-07	武汉工程大学	一种吡唑并[1,2-a][1,2,4]三嗪-3,6-二酮衍生物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19962924A1 (de) *	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) *	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
DE10342570A1 (de)	2003-09-15	2005-04-14	Bayer Healthcare Ag	Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
US20080051578A1 (en) *	2006-08-24	2008-02-28	Georg Dahmann	Substituted biaryls, process for their manufacture and use thereof as medicaments
WO2008140220A1 (en) *	2007-05-09	2008-11-20	Legochem Bioscience Ltd.	Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof

2008
- 2008-07-03 KR KR1020080064178A patent/KR100898361B1/ko active Active
2009
- 2009-06-05 JP JP2011516114A patent/JP5325289B2/ja active Active
- 2009-06-05 AU AU2009266631A patent/AU2009266631B2/en active Active
- 2009-06-05 US US13/002,271 patent/US8178525B2/en active Active
- 2009-06-05 WO PCT/KR2009/003008 patent/WO2010002115A2/en not_active Ceased
- 2009-06-05 NZ NZ590315A patent/NZ590315A/xx unknown
- 2009-06-05 BR BRPI0915326A patent/BRPI0915326B8/pt active IP Right Grant
- 2009-06-05 ES ES09773651.6T patent/ES2566755T3/es active Active
- 2009-06-05 MY MYPI2010006218A patent/MY165573A/en unknown
- 2009-06-05 RU RU2011103766/04A patent/RU2468024C2/ru active
- 2009-06-05 CA CA2728350A patent/CA2728350C/en active Active
- 2009-06-05 EP EP09773651.6A patent/EP2307407B1/en active Active
- 2009-06-05 UA UAA201101142A patent/UA97598C2/ru unknown
- 2009-06-05 CN CN200980125825.3A patent/CN102083825B/zh active Active
- 2009-06-05 MX MX2010013969A patent/MX2010013969A/es active IP Right Grant
2010
- 2010-12-29 CL CL2010001618A patent/CL2010001618A1/es unknown
- 2010-12-30 IL IL210384A patent/IL210384A/en active IP Right Grant

Also Published As

Publication number	Publication date
EP2307407B1 (en)	2016-03-16
NZ590315A (en)	2012-11-30
RU2011103766A (ru)	2012-08-10
CA2728350C (en)	2013-09-24
WO2010002115A2 (en)	2010-01-07
BRPI0915326B8 (pt)	2021-05-25
RU2468024C2 (ru)	2012-11-27
UA97598C2 (ru)	2012-02-27
AU2009266631A1 (en)	2010-01-07
CN102083825B (zh)	2014-07-30
JP2011526624A (ja)	2011-10-13
ES2566755T3 (es)	2016-04-15
AU2009266631B2 (en)	2012-03-15
CN102083825A (zh)	2011-06-01
MY165573A (en)	2018-04-05
CA2728350A1 (en)	2010-01-07
US8178525B2 (en)	2012-05-15
US20110112083A1 (en)	2011-05-12
KR100898361B1 (ko)	2009-05-20
WO2010002115A3 (en)	2010-03-11
EP2307407A2 (en)	2011-04-13
IL210384A (en)	2014-09-30
CL2010001618A1 (es)	2011-10-28
IL210384A0 (en)	2011-03-31
BRPI0915326B1 (pt)	2021-04-06
JP5325289B2 (ja)	2013-10-23
EP2307407A4 (en)	2011-08-24
MX2010013969A (es)	2011-05-02

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-06-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-11-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-12-01	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-03-23	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-04-06	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI1009324A2 (pt)	2015-11-24	compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0918502A2 (pt)	2015-12-01	aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BRPI0815606A2 (pt)	2015-03-03	Derivados de 6-triazol piridazina - sulfanil benzotiazol e benzimidazol, o respectivo processo de preparo, a respectiva aplicação a título de medicamentos, composições farmacêuticas e utilização, notadamente como inibidores de met.
BR112013016772A2 (pt)	2016-10-11	composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
IL222878A (en)	2016-11-30	N - ((2-oxo-2,1-dihydropyridine-3-ram) methyl) -1h-indole-4-carboxamide and pharmaceuticals containing them
BR112012022878A2 (pt)	2016-06-14	composto, composição farmacêutica, uso do compostos e método de tratamento
BR112012022879A2 (pt)	2016-06-14	composto, composição farmacêutica, uso do composto e método de tratamento
BR112013013790A2 (pt)	2016-09-13	compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
BRPI0906962A2 (pt)	2015-07-14	Composto, e, composição farmacêutica
BRPI0906556A2 (pt)	2015-07-07	Composto, e, composição farmacêutica
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
ATE541850T1 (de)	2012-02-15	Pyrroloä2,3-cüpyridinderivate als p38-kinase- hemmende mittel
BRPI0915897A2 (pt)	2015-11-03	compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BRPI0913726A2 (pt)	2015-10-13	rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BR112014001991A2 (pt)	2017-02-21	certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos
BRPI0915120A2 (pt)	2016-07-26	composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0822337A2 (pt)	2015-06-16	Folatos, composições e usos dos mesmos
BRPI1014583A2 (pt)	2016-04-26	sulfonamidas heterocíclicos, composições farmacêuticas e usos do mesmo.
BR112012003842A2 (pt)	2016-03-22	composição farmacêutica, método de formulação e uso da mesma
BR112012006404A2 (pt)	2016-04-12	derivados de di-hidropteridinona, processo de preparação e uso farmacêutico dos mesmos
BRPI0915680A2 (pt)	2019-09-24	miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
BRPI0917681A2 (pt)	2015-08-04	Composto, e, composição farmacêutica
DK2242740T3 (da)	2013-03-25	SF5-derivater som par1-inhibitorer, deres fremstilling og anvendelse som lægemidler
EP2429987A4 (en)	2012-10-03	AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
IL232035A0 (en)	2014-05-28	Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof